查看2014.Doxorubicin.HSA的源代码

===  '''治疗后的反应和结果 (Response and outcome following therapy)''' === 

接受DOX治疗的64只狗（100%）有可供分析的结果信息，这些数据总结在表4和表5中。一只狗没有接受预定的反应评估超声心动图，因此没有相关的反应信息;但是，提供了这只狗的生存数据。客观缓解率为41%，生物缓解率（CR+PR+SD）或临床获益为68%。20 只狗 （32%） 对 DOX 治疗没有反应。图 2 和 3 分别显示了 DOX 治疗犬的 PFS 和 DOX 和 CTL 组犬的 OS 的 Kaplan-Meier 生存概率曲线。在确定PFS之前，有三只狗失去了随访，因此从该分析中被删失。在确定 OS 之前，有 6 只狗丢失了随访，另外 4 只狗死于与 HSA 无关的原因;这 10 只狗从操作系统分析中被删失。DOX治疗组狗的PFS和MST分别为66天和116天。未经治疗的 CTL 犬的 MST 为 12 天。

Sixty-four dogs (100%) undergoing treatment with DOX had outcome information available for analysis, and these data are summarized in Tables 4 and 5. One dog did not undergo the scheduled response assessment echocardiogram and thus did not have associated response information available; however, survival data are provided for this dog. The objective response rate was 41%, and the biologic response rate (CR+PR+SD), or clinical benefit, was 68%. Twenty dogs (32%) failed to respond to treatment with DOX. Kaplan–Meier survival probability curves illustrating PFS for DOX-treated dogs and OS for dogs in both the DOX and CTL groups are presented in Figs 2 and 3, respectively. Three dogs were lost to follow-up before PFS could be determined and were thus censored from this analysis. Six dogs were lost to follow-up before OS could be determined and an additional four dogs died from causes unrelated to HSA; these 10 dogs were censored from OS analysis. The PFS and MST for dogs in the DOX-treated group were 66 and 116 days, respectively. The MST for untreated CTL dogs was 12 days.